What's Happening?
Neuroscientist Cristin Welle, PhD, and her team at CU Anschutz have discovered that vagus nerve stimulation (VNS) may promote myelin regrowth in individuals with multiple sclerosis (MS). This research, initially conducted on animal models and subsequently
in a small human pilot study, has shown promising results, leading to a phased National Institutes of Health grant to further their work. The studies indicated a notable increase in new oligodendrocytes, which are cells responsible for producing myelin, the protective coating around nerve fibers that is damaged in MS. Furthermore, brain images suggested that the regenerated myelin in animal models was returning to its original locations, a phenomenon referred to as myelin pattern recovery, which is linked to improvements in motor function. This approach draws parallels from the successful application of VNS in stroke rehabilitation, where electrical bursts stimulate brain cell regeneration.
Why It's Important?
This development holds significant importance for the nearly 1 million MS patients in the U.S., offering a potential new therapeutic avenue beyond existing medications. MS is a neurodegenerative autoimmune disease that disproportionately affects women and can lead to severe disabilities, including loss of mobility, vision, and hand function, due to the body attacking its own myelin sheath. Current treatments primarily focus on managing symptoms and slowing disease progression, but VNS could offer a way to repair the underlying damage. By promoting myelin regeneration, VNS has the potential to restore motor and cognitive abilities that are often lost due to the disease. This research also highlights the potential of neuromodulation therapies to precisely target affected brain areas, harnessing the body's natural repair mechanisms, which could be particularly beneficial for patients who do not respond well to pharmaceutical solutions.
What's Next?
The CU Anschutz team plans to continue its basic science research in the lab and, following feasibility requirements, will translate their findings into a clinical trial. They anticipate beginning recruitment for this trial by mid-2027. The clinical trial will focus on individuals with relapsing-remitting MS who experience hand dexterity issues, a common symptom affecting 75% of MS patients. Unlike current stroke VNS programs that involve implanted devices, this trial will utilize a non-invasive method of stimulation via the ear, where a small branch of the vagus nerve is accessible. The long-term vision is to develop an at-home system using this ear-stimulation technology. Additionally, the team, led by Jeffrey Bennett, MD, PhD, will develop advanced magnetic resonance sequencing to precisely track myelin state in the brain and investigate the role of immune system-related microglial cells in myelin recovery.
Beyond the Headlines
The potential success of VNS in treating MS could represent a paradigm shift in how neurodegenerative diseases are approached, moving beyond symptom management to actual repair of neurological damage. This research underscores the growing understanding of neuroplasticity and the body's inherent capacity for healing when appropriately stimulated. The non-invasive nature of ear-based VNS could significantly improve patient accessibility and quality of life, reducing the need for surgical implants. Furthermore, the exploration of microglial cells' role in myelin recovery could unlock deeper insights into the immune system's involvement in MS and other autoimmune conditions, potentially leading to more targeted and effective treatments. This innovative approach could also inspire further research into neuromodulation for a broader range of neurological disorders where current treatments are limited.
